MongoDB (MDB) stock drops nearly 5% to start 2026 — here’s what investors are watching next
3 January 2026
1 min read

MongoDB (MDB) stock drops nearly 5% to start 2026 — here’s what investors are watching next

NEW YORK, Jan 2, 2026, 20:46 ET — Market closed

  • MongoDB closed down 4.8% at $399.65 on Friday, lagging a selloff in software stocks.
  • The software-sector ETF IGV fell 2.9% on the day, highlighting pressure on high-growth tech.
  • MongoDB’s next earnings are estimated for March 4 after the close, based on past reporting schedules, according to MarketBeat. 1

MongoDB, Inc. (MDB) shares closed down 4.8% at $399.65 on Friday, deepening a pullback across software stocks as investors trimmed risk on the first trading day of 2026.

The decline matters because MongoDB has been one of the stronger large-cap software names in recent months, a setup that can magnify moves when sentiment turns.

High-growth software stocks often trade on expectations for future cash flows, which can make them more sensitive than the broader market to shifts in risk appetite.

The iShares Expanded Tech-Software Sector ETF fell 2.9% on the day, while the Nasdaq 100 tracking fund QQQ slipped about 0.2% and the S&P 500 tracker SPY rose about 0.2%.

MongoDB traded between $392.86 and $432.70 on Friday, and volume topped 2.5 million shares, above its average, market data showed.

Some analysts stayed positive despite the volatility. Mark Cash at Raymond James called MongoDB one of the “most strategically important independent database platforms,” according to a note cited by Insider Monkey.

MarketBeat’s tally of 41 analyst ratings puts MongoDB at “Moderate Buy” and shows an average 12-month price target of $414.97 — about 4% above Friday’s close. 2

Investors remain anchored to MongoDB’s last quarterly report. The company posted third-quarter fiscal 2026 revenue of $628.3 million, up 19% from a year earlier, and said Atlas — its managed cloud database service — made up about 75% of total revenue.

On an earnings-per-share basis — a measure of profit allocated to each share — MongoDB reported EPS of $1.32 on Dec. 1, beating a consensus estimate of $0.79, according to MarketBeat’s earnings summary. 1

The next key catalyst is the next set of results. MarketBeat estimates MongoDB will report fourth-quarter figures on March 4 after the market closes, based on past reporting schedules. 1

Before next session, traders will watch whether MongoDB can regain the $400 level after dipping below it on Friday; the stock’s 52-week high is $441.70 and its low is $170.30.

Before next session, investors will be focused on whether Atlas growth and customer spending trends stay resilient — a key watchpoint for subscription and usage-driven cloud software models.

Before next session, any further weakness in the broader software group could keep pressure on MongoDB, after IGV’s nearly 3% drop on Friday.

In extended trading — buying and selling outside the regular 9:30 a.m. to 4:00 p.m. ET session — MongoDB was little changed at $399.50 as of 7:59 p.m. ET, MarketBeat data showed. 1

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

7 February 2026
Saudi Exchange approved Merrill Lynch KSA’s exit as market maker for Saudi Aramco, effective Feb. 8. Aramco shares closed at 25.60 riyals Thursday, down 0.06, with 22.1 million traded. The Tadawul index fell 1.3% as Brent crude dropped to $67.93. Aramco set March official selling prices at $2.10 above Argus for North America and $0.65 above ICE Brent for Western Europe.
Confluent (CFLT) stock slips to $30 as IBM’s $31 deal caps upside — what investors watch next
Previous Story

Confluent (CFLT) stock slips to $30 as IBM’s $31 deal caps upside — what investors watch next

P&G stock drops again as 2026 opens — earnings date and key levels in focus
Next Story

P&G stock drops again as 2026 opens — earnings date and key levels in focus

Go toTop